Lupin launches generic drug in US market

Lupin, a Mumbai-based pharmaceutical company, has launched an FDA-approved generic version of Myrbetriq extended-release tablets. These tablets are used for treating overactive bladder symptoms. Lupin's shares rose by 3.38% following the announcement.

Mumbai-based drug maker has introduced the medication after receiving an approval from the US Food and Drug Administration (USFDA), Lupin said in a statement.

The company's product is a generic equivalent of Astellas Pharma Global Development, Inc's Myrbetriq extended-release tablets, it added.

Mirabegron extended-release tablets are used to treat certain bladder problems including overactive bladder.

Lupin shares were trading 3.38 per cent up at Rs 1,599.35 apiece on the BSE.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)